PHOENIX, AZ, Breakthru Medicine has emerged from stealth with the close of a $60M Series A financing round following a prior undisclosed seed round.
Breakthru Medicine has emerged from stealth with the close of a $60M Series A financing round following a prior undisclosed seed round.
Breakthru was founded by biotech industry veterans Steve Potts, PhD, Mark Mulvihill, PhD, and Brian Barnett, MD, to deliver disruptive therapeutic modalities to cancer patients to address major unmet medical needs.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.